Back to articles

Cardiovascular risks increased with use of inhaled long-acting bronchodilators


New use of long-acting beta-2 agonists (LABAs) or long-acting antimuscarinic antagonists (LAMAs) in patients with chronic obstructive pulmonary disease (COPD) was associated with a 1.5-fold increased risk of cardiovascular (CV) events within 30 days of treatment initiation, according to a nested case-control study in JAMA Internal Medicine.

Recent Articles